Clinical Application of PET in Head and Neck Cancer.
- Author:
Jae Seung KIM
1
;
Jai Hyuen LEE
Author Information
1. Department of Nuclear Medicine, Asan Medical Center,University of Ulsan College of Medicine, Seoul, Korea. jaeskim@amc.seoul.kr
- Publication Type:Review
- Keywords:
head and neck;
FDG;
PET;
staging;
squamous cell carcinoma
- MeSH:
Carcinoma, Squamous Cell;
Fluorodeoxyglucose F18;
Glucose;
Head and Neck Neoplasms*;
Head*;
Humans;
Inpatients;
Neck
- From:Hanyang Medical Reviews
2007;27(4):16-22
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Head and neck cancers are the sixth most common type of human cancer worldwide. Squamous cell carcinomas are the most common cancer of the head and neck. Due to the higher glycolytic rates of squamous cell carcinomas relative to normal tissue, the glucose analog 18F-FDG can be used to detect umors, and 18F-FDG PET has been used inpatients with head and neck cancers for initial staging, management of recurrent cancers, and therapeutic onitoring. We reviewed the clinical application and diagnostic usefulness of 18F-FDG PET in the management of head and neck cancer.
